Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C30H60N3O3 |
| Molecular Weight | 510.8157 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 3 |
SHOW SMILES / InChI
SMILES
CC[N+](CC)(CC)CCOC1=CC=CC(OCC[N+](CC)(CC)CC)=C1OCC[N+](CC)(CC)CC
InChI
InChIKey=OZLPUNFFCJDMJD-UHFFFAOYSA-N
InChI=1S/C30H60N3O3/c1-10-31(11-2,12-3)22-25-34-28-20-19-21-29(35-26-23-32(13-4,14-5)15-6)30(28)36-27-24-33(16-7,17-8)18-9/h19-21H,10-18,22-27H2,1-9H3/q+3
Gallamine triethiodide is a synthetic nondepolarizing blocking drug, which is allosteric antagonist of muscarinic M2 acetylcholine receptor and inhibitor of acetylcholinesterase. It was used under brand name flaxedil to stabilize muscle contractions during surgical procedures. However, this usage was discontinued. It was shown, that gallamine caused tachycardia by depressing the vagus nerve and, occasionally, hypertension and increased cardiac output.
CNS Activity
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: P08172 Gene ID: 1129.0 Gene Symbol: CHRM2 Target Organism: Homo sapiens (Human) |
|||
Target ID: P22303|||Q53F46 Gene ID: 43.0 Gene Symbol: ACHE Target Organism: Homo sapiens (Human) |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Palliative | FLAXEDIL Approved UseUnknown |
Doses
| Dose | Population | Adverse events |
|---|---|---|
40 mg single, intrathecal Accidental dose Dose: 40 mg Route: intrathecal Route: single Dose: 40 mg Sources: |
unhealthy, 33 years n = 1 Health Status: unhealthy Age Group: 33 years Sex: M Population Size: 1 Sources: |
Other AEs: Convulsions... |
6 mg/kg single, intravenous Highest studied dose Dose: 6 mg/kg Route: intravenous Route: single Dose: 6 mg/kg Sources: |
unhealthy n = 7 |
|
100 mg single, intravenous Dose: 100 mg Route: intravenous Route: single Dose: 100 mg Sources: |
unhealthy |
Other AEs: Ventricular tachycardia... |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Convulsions | 40 mg single, intrathecal Accidental dose Dose: 40 mg Route: intrathecal Route: single Dose: 40 mg Sources: |
unhealthy, 33 years n = 1 Health Status: unhealthy Age Group: 33 years Sex: M Population Size: 1 Sources: |
|
| Ventricular tachycardia | 100 mg single, intravenous Dose: 100 mg Route: intravenous Route: single Dose: 100 mg Sources: |
unhealthy |
Sample Use Guides
The mechanisms of action of gallamine on nerve terminals, cholinergic receptors, and the threshold for propagation of end-plate potentials to the muscle fiber were investigated in rat phrenic nerve-diaphragm preparations. Intracellular studies were made with glass microelectrodes to determine changes in end-plate potentials and miniature end-plate potentials produced by gallamine at concentrations between 10(-7) M to 10(-4) M. Gallamine excited and then depressed the release of transmitter from nerve terminals.
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
3450
Created by
admin on Fri Dec 15 16:25:28 GMT 2023 , Edited by admin on Fri Dec 15 16:25:28 GMT 2023
|
PRIMARY | |||
|
VYJ027LZ05
Created by
admin on Fri Dec 15 16:25:28 GMT 2023 , Edited by admin on Fri Dec 15 16:25:28 GMT 2023
|
PRIMARY | |||
|
DTXSID5048392
Created by
admin on Fri Dec 15 16:25:28 GMT 2023 , Edited by admin on Fri Dec 15 16:25:28 GMT 2023
|
PRIMARY | |||
|
7006-17-9
Created by
admin on Fri Dec 15 16:25:28 GMT 2023 , Edited by admin on Fri Dec 15 16:25:28 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
